Ossify DBM Cortial Fiber

Cortical Fibers Technology

OSSIFY DBM FIBER

EASY TO USE

OSSIFY DBM Fiber Technology consists of 100% Demineralized Cortical Bone, creating a malleable porous structure when hydrated with any bioactive agent. The porous matrix provides an excellent osteoconductive scaffold with increased osteoinductive potential based on its larger surface area.

OSSIFY DBM Fiber Technology offers a combination of a porous surface structure and a bulk fibrous structure. This combination simultaneously provides a porous host for endogenous cells, and serves an attractive protein binding site for cell signaling to promote chemotaxis. OSSIFY DBM Fiber can serve as a superior vehicle for tissue integration when combined with the inherent biochemical properties of the scaffold.

THOROUGHLY TESTED FOR
  • Antibodies to the Human Immunodeficiency Virus, Type 1 and Type 2 (Anti-HIV-1 and Anti-HIV-2)
  • Nucleic Acid Test (NAT) for HIV-1
  • Hepatitis B Surface Antigen (HBsAg)
  • Nucleic Acid Test (NAT) for the Hepatitis B Virus (HBV)
  • Total Antibodies to Hepatitis B Core Antigen (Anti-HBc—Total, Meaning IgG and IgM)
  • Antibodies to the Hepatitis C Virus (Anti-HCV);
  • Nucleic Acid Test (NAT) for HCV
  • Syphilis
Catalog No. Volume
OST-T-500 Cartridge 5 CC
OST-T-1000 Cartridge 10 CC
OS-S-01 1 CC
OS-S-02 2.5 CC
OS-S-05 5 CC
0S-S-10 10 CC
SAFE

American Association of Tissue Bank (AATB) accredited. DBM is terminally sterilized using validated e-beam irradiation. Recovery and Screening performed according to FDA and AATB guidelines.

INDICATIONS FOR USE

The graft is indicated for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. It should be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities, spine, and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The graft provides a bone void filler that resorbs and is replaced by the growth of new bone during the healing process. It can be mixed with autogenous bone marrow prior to use at the physician’s discretion.